Lee David C, Varela Aurore, Kostenuik Paul J, Ominsky Michael S, Keaveny Tony M
O.N. Diagnostics LLC, Berkeley, CA, USA.
Charles River Laboratories Inc., Montréal, QC, Canada.
J Bone Miner Res. 2016 Aug;31(8):1586-95. doi: 10.1002/jbmr.2830. Epub 2016 Apr 25.
Finite element analysis has not yet been validated for measuring changes in whole-bone strength at the hip or spine in people after treatment with an osteoporosis agent. Toward that end, we assessed the ability of a clinically approved implementation of finite element analysis to correctly quantify treatment effects on vertebral strength, comparing against direct mechanical testing, in cynomolgus monkeys randomly assigned to one of three 16-month-long treatments: sham surgery with vehicle (Sham-Vehicle), ovariectomy with vehicle (OVX-Vehicle), or ovariectomy with denosumab (OVX-DMAb). After treatment, T12 vertebrae were retrieved, scanned with micro-CT, and mechanically tested to measure compressive strength. Blinded to the strength data and treatment codes, the micro-CT images were coarsened and homogenized to create continuum-type finite element models, without explicit porosity. With clinical translation in mind, these models were then analyzed for strength using the U.S. Food and Drug Administration (FDA)-cleared VirtuOst software application (O.N. Diagnostics, Berkeley, CA, USA), developed for analysis of human bones. We found that vertebral strength by finite element analysis was highly correlated (R(2) = 0.97; n = 52) with mechanical testing, independent of treatment (p = 0.12). Further, the size of the treatment effect on strength (ratio of mean OVX-DMAb to mean OVX-Vehicle, as a percentage) was large and did not differ (p = 0.79) between mechanical testing (+57%; 95% CI [26%, 95%]) and finite element analysis (+51% [20%, 88%]). The micro-CT analysis revealed increases in cortical thickness (+45% [19%, 73%]) and trabecular bone volume fraction (+24% [8%, 42%]). These results show that a preestablished clinical finite element analysis implementation-developed for human bone and clinically validated in fracture-outcome studies-correctly quantified the observed treatment effects of denosumab on vertebral strength in cynomolgus monkeys. One implication is that the treatment effects in this study are well explained by the features contained within these finite element models, namely, the bone geometry and mass and the spatial distribution of bone mass. © 2016 American Society for Bone and Mineral Research.
有限元分析尚未在接受骨质疏松症药物治疗的人群中,用于验证髋部或脊柱全骨强度的变化情况。为此,我们评估了一种经临床批准的有限元分析方法,在随机分配接受三种为期16个月治疗之一的食蟹猴中,与直接力学测试相比,正确量化对椎体强度治疗效果的能力:假手术加赋形剂(假手术-赋形剂组)、卵巢切除术加赋形剂(去卵巢-赋形剂组)或卵巢切除术加地诺单抗(去卵巢-地诺单抗组)。治疗后,取出T12椎体,用微型计算机断层扫描(micro-CT)进行扫描,并进行力学测试以测量抗压强度。在不知道强度数据和治疗编码的情况下,将micro-CT图像进行粗化和均质化处理,以创建无明确孔隙率的连续型有限元模型。考虑到临床转化,然后使用美国食品药品监督管理局(FDA)批准的VirtuOst软件应用程序(O.N. Diagnostics,美国加利福尼亚州伯克利)对这些模型进行强度分析,该软件是为分析人体骨骼而开发的。我们发现,通过有限元分析得出的椎体强度与力学测试高度相关(R² = 0.97;n = 52),且与治疗无关(p = 0.12)。此外,强度治疗效果的大小(平均去卵巢-地诺单抗组与平均去卵巢-赋形剂组的比值,以百分比表示)很大,在力学测试(+57%;95%置信区间[26%,95%])和有限元分析(+51% [20%,88%])之间没有差异(p = 0.79)。micro-CT分析显示皮质厚度增加(+45% [19%,73%])和小梁骨体积分数增加(+24% [8%,42%])。这些结果表明,一种预先建立的临床有限元分析方法——为人体骨骼开发并在骨折结局研究中得到临床验证——正确地量化了地诺单抗对食蟹猴椎体强度的观察到的治疗效果。一个启示是,本研究中的治疗效果可以很好地由这些有限元模型所包含的特征来解释,即骨骼几何形状、质量以及骨质量的空间分布。© 2016美国骨与矿物质研究学会。